Compare IFBD & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IFBD | SILO |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 379.7K |
| IPO Year | 2020 | 2011 |
| Metric | IFBD | SILO |
|---|---|---|
| Price | $1.00 | $2.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.3K | ★ 51.3K |
| Earning Date | 05-01-2023 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.22 |
| 52 Week High | $2.18 | $7.95 |
| Indicator | IFBD | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 26.09 |
| Support Level | $0.99 | $0.30 |
| Resistance Level | $1.10 | $4.80 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 54.45 | 8.31 |
Infobird Co Ltd is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. The Company provides standard and customized customer relationship management cloud-based services, including SaaS and business process outsourcing (BPO) services. It generates revenue from the development and sale of software licenses for customized software, as well as from business integration solution services and digital advertising and marketing campaign services. Digital advertising revenue is generated from developing and executing advertising plans based on customer needs, and the Company generally provides limited warranties for work performed under its business integration solution contracts. The Company generates maximum revenue from its operations in Mainland China.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.